Cencora, Inc. (NYSE:COR) is Quantbot Technologies LP’s 5th Largest Position

Quantbot Technologies LP reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 35.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 84,940 shares of the company’s stock after selling 46,617 shares during the quarter. Cencora makes up 0.7% of Quantbot Technologies LP’s investment portfolio, making the stock its 5th biggest holding. Quantbot Technologies LP’s holdings in Cencora were worth $19,084,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Sciencast Management LP purchased a new position in shares of Cencora in the 4th quarter valued at $243,000. Millstone Evans Group LLC purchased a new position in shares of Cencora during the fourth quarter worth about $131,000. Adams Diversified Equity Fund Inc. grew its holdings in shares of Cencora by 17.1% during the fourth quarter. Adams Diversified Equity Fund Inc. now owns 81,000 shares of the company’s stock worth $18,199,000 after purchasing an additional 11,800 shares during the last quarter. Whittier Trust Co. increased its position in shares of Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock worth $1,765,000 after purchasing an additional 44 shares in the last quarter. Finally, Symmetry Partners LLC lifted its holdings in shares of Cencora by 8.2% in the 4th quarter. Symmetry Partners LLC now owns 968 shares of the company’s stock valued at $218,000 after purchasing an additional 73 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,648 shares of company stock valued at $3,382,462 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on COR shares. JPMorgan Chase & Co. raised their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday. Wells Fargo & Company raised their price objective on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Finally, Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Stock Up 0.6 %

COR opened at $255.64 on Friday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $263.70. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The business has a 50 day simple moving average of $247.01 and a 200-day simple moving average of $238.93. The stock has a market capitalization of $49.57 billion, a P/E ratio of 36.36, a P/E/G ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.